We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





BBI Solutions Showcases Mobile Solutions Capabilities at AACC 2019

By LabMedica International staff writers
Posted on 06 Aug 2019
BBI Solutions (Crumlin, UK) demonstrated how its lateral flow software is making point-of-care testing (POCT) more accurate, efficient and easier to use than ever before at the world’s largest laboratory medicine trade show, American Association for Clinical Chemistry (AACC) exhibition.

BBI Solutions are leading experts in immunoassay development & manufacturing services, offering an extensive portfolio of diagnostic products globally. More...
At the AACC Clinical Lab Expo, BBI’s mobile arm, Novarum, launched a demonstrator app that can read the results of an imitated malaria test. Novarum is an easy-to-use mobile app enabling rapid POCT, using just a smartphone. Novarum’s technology accurately interprets the results of lateral flow assays while offering test choreography and tracking disease outbreaks, providing clients with a competitive advantage within the diagnostic landscape. At the tradeshow, the company demonstrated how mobile technology can remove complexities from lateral flow testing to enable healthcare professionals or patients to deliver lab quality results in the field.

Novarum’s innovative mobile technology mitigates the risks identified around lateral flow by the Clinical Laboratory Improvement Amendments (CLIA), which establishes quality standards for all laboratory testing to ensure the accuracy, reliability and timeliness of patient test results. The company demonstrated every aspect of its immunoassay development - feasibility and planning, reagent supply and manufacturing, custom antibody development, custom conjugations, lateral flow development and manufacturing, as well as Novarum’s smartphone reader capability which enables immediate, POC diagnosis.

“This is an exciting opportunity to, once again, showcase BBI Solutions’ comprehensive suite of capabilities at the AACC expo. We’re particularly excited to be launching our demo app at the event this year, which enables us to demonstrate every aspect of Novarum’s capability that a potential customer could include in a custom-built app,” said John Hanson, Chief Commercial Officer at BBI Solutions. “We want to help our customers envision what it would be like for the healthcare professional or patient using the test and to highlight how Novarum’s software mitigates the risks identified around lateral flow testing.”


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.